13 completed, 7 recruiting, 4 unknown, 3 withdrawn. 31 Phase 1, 16 Phase 2.
Follow PM 01183: new trials by email Literature Review of PM 01183 trials Research Report on PM 01183
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 166 | 2026-02-23 | 2026-03-11 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2024-10-31 | 2024-11-18 | |
| Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer Lurbinectedin, Dostarlimab - Endometrial Cancer | Phase 1 / Phase 2 | Withdrawn | Vall d'Hebron Institute of Oncology | 2024-05-01 | 2025-04-01 | |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| Lurbinectedin in FET-Fused Tumors Lurbinectedin - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 63 | 2023-07-27 | 2026-09-02 |
| Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer Paclitaxel, Bevacizumab, Lurbinectedin - Ovarian Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 34 | 2023-07-12 | 2026-08-20 |
| LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma Lurbinectedin - Advanced Soft-tissue Sarcoma | Phase 1 / Phase 2 | Unknown | ERLINDA M GORDON | 40 | 2023-06-07 | 2024-07-05 |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Lurbinectedin - Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Jazz Pharmaceuticals | 60 | 2023-05-23 | 2026-11-05 |
| Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer Lurbinectedin, Palliative Radiation Therapy - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 22 | 2022-07-27 | 2025-10-31 |
| Lurbinectedin + Doxorubicin In Leiomyosarcoma Lurbinectedin, Doxorubicin - Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | Massachusetts General Hospital | 62 | 2022-02-04 | 2026-08-27 |
| Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride - Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-09-15 | 2022-02-10 | |
| Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers Lurbinectedin, Berzosertib - SCLC, Small Cell Cancer | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 37 | 2021-06-01 | 2026-03-17 |
| Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment Lurbinectedin - Advanced Solid Tumor, Hepatic Impairment | Phase 1 | Unknown | PharmaMar | 24 | 2021-03-09 | 2023-11-27 |
| Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors Lurbinectedin, Bosentan - Advanced Solid Tumor | Phase 1 | Completed | PharmaMar | 11 | 2021-01-14 | 2025-09-16 |
| Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients Lurbinectedin for injection - Advanced Solid Tumor | Phase 1 | Completed | Luye Pharma Group Ltd. | 32 | 2020-11-24 | 2024-06-10 |
| Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC Nivolumab, Ipilimumab, Lurbinectedin - Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 9 | 2020-11-23 | 2024-04-02 |
| Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors Lurbinectedin alone, Lurbinectedin+Itraconazole co-administration - Advanced Solid Tumors | Phase 1 | Completed | PharmaMar | 14 | 2020-10-07 | 2025-09-02 |
| Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. Lurbinectedin, Pembrolizumab - Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | Antonio Calles Blanco | 28 | 2020-09-21 | 2025-06-04 |
Showing 20 of 31. Sign in to see all of them.
Small Cell Lung Carcinoma (8) · Neoplasms (5) · Breast Neoplasms (3) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Sarcoma (3) · Sarcoma, Ewing (3) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Neuroendocrine Tumors (2) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Desmoplastic Small Round Cell Tumor (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
PharmaMar (12) · M.D. Anderson Cancer Center (2) · Antonio Calles Blanco (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Children's Hospital of Philadelphia (1) · ERLINDA M GORDON (1) · Emory University (1) · Fundacion Oncosur (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jazz Pharmaceuticals (1) · Luye Pharma Group Ltd. (1) · Massachusetts General Hospital (1) · Misty Shields (1) · National Cancer Institute (NCI) (1) · Phanes Therapeutics (1)
United States (17) · Spain (12) · Switzerland (3) · United Kingdom (3) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Italy (1)
Rubin Lubomirov, MD, PhD (2) · Alberto A Chiappori, MD (1) · Andres Poveda, MD (1) · Anish Thomas, M.D. (1) · Antonio Calles (1) · Erlinda M Gordon, MD (1) · Gregory Cote, M.D. Ph.D (1) · Josep Tabernero, MD (1) · Kristin Higgins, MD (1) · Mark Ratain, MD (1) · Misty D Shields, MD, PhD (1) · Robert S Benjamin (1) · Santiago Ponce, MD (1)
PMID 33914350, PMID 24563480, PMID 33704620, PMID 34453241, PMID 37491889, PMID 38351146, PMID 39938593, PMID 40963055, PMID 41791703, PMID 42081171
P30CA138292 (1)